The patients recruited included those with histologically confirmed locally advanced or metastatic solid HER2-overexpressing (immunohistochemistry +2/+3) tumours across seven different disease groups, including BTCs (n = 41), that had progressed or were refractory to alternative systemic treatment options (including prior HER2 therapy). This evidence concerns the gene ERBB2 and neoplasm.